When data integrity becomes a structural outcome
Data integrity reflects how your analytical data is generated, governed and secured across your product lifecycle.
When analytical data is generated across multiple laboratories, systems and partners, integrity issues rarely appear suddenly.
What drives data integrity risks ?
- inconsistent investigation practices,
- fragmented audit trails across systems,
- reduced visibility over method changes,
- increasing effort to prepare for inspections.
Individually, these issues may remain manageable. Together, they increase pressure as your programmes mature and inspections approach.
Our approach
We believe data integrity is not reinforced at the end of your development. It is built through the way your analytical data is generated, governed and protected over time.
By centralising analytics within one integrated analytical environment, we provide you with:
- one harmonised analytical quality system, covering OOS/OOT management, change control and CAPA,
- consistent audit trails and full data traceability across methods, studies and phases,
- standardised documentation and reporting, applied consistently across programmes, compliant with EMA and FDA expectations
- continuity of analytical knowledge throughout your product lifecycle.
As a result, inspection readiness becomes a structural outcome of your analytical model, not a last‑minute effort.
Why it’s worth discussing?
A focused discussion can help you:
- identify integrity risks early,
- simplify your analytical governance,
- reduce your inspection‑related stress,
- strengthen scientific justification ahead of regulatory interactions.